Sphingomyelin as a key negative mediator in atrial fibrillation via lipid profiling analysis and functional identification

Clicks: 25
ID: 329312
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #44 of 136 articles by views in EP Europace

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 136 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
AIMS: Atrial fibrillation (AF) has emerged as one of the most prevalent cardiac arrhythmias globally, with its incidence continuously rising, thereby elevating it to a major public health concern. The heart is known for its high lipid content, and disorders or abnormalities in lipid metabolism are frequently associated with cardiovascular diseases. This study aims to investigate the regulatory roles of lipids in AF. METHODS AND RESULTS: Using tree-based ensemble learning-assisted lipidomics, sphingomyelin was identified as a key differential metabolite and found to be significantly reduced in AF patients. Exogenous supplementation of sphingomyelin significantly attenuated Ach-CaCl2- and Ang II-induced AF, fibrosis, and inflammation in mice. Furthermore, decreased sphingomyelin levels were attributed to increased activity of sphingomyelin phosphodiesterases (SMPDs) under AF conditions. Mechanistically, RNA-Seq analysis demonstrated that sphingomyelin inhibits AF-induced activation of the Rap1 signaling pathway, a finding corroborated by overexpression and knockdown of RAP1 in vivo. CONCLUSION: Together, these findings highlight the therapeutic potential of sphingomyelin and SMPD inhibitors in mitigating AF through inhibition of the Rap1 signaling pathway, thereby establishing the targeting of sphingomyelin metabolism as a viable and novel treatment strategy for AF.
Reference Key
openalex_W7213910733 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Linlin Wang, Anqi Shi, Daixin Yu, Zhengmeng Jiang, Qianqian Chen, Xiaoxuan Yu, Cheng Qu, An Pan
Are you one of these authors? Claim your profile
Journal EP Europace
Year 2026
DOI
10.1093/europace/euag270
URL
https://doi.org/10.1093/europace/euag270
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.